Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

Announced by Genentech on July 04, 2024, the prefilled, 6.0 mg syringe is designed to improve ease of administration and offer ophthalmologists with a ready-to-use version of the bispecific antibody.

In the endocrinology month in review, we spotlight top news in the endocrinology pipeline and the most important updates from ADA 2024.

The biosimilars month in review underscores the efficacy and safety of biosimilars in rheumatology, including recent studies supporting the growing confidence in these treatments across disease spaces.

Patients with chronic kidney disease and TSAT levels of 30–40% experienced significantly fewer cardiovascular events than those with TSAT of 20–30%.

This analysis from Spain assessed the short-term effectiveness and safety of abrocitinib within a real-world setting for those with moderate-to-severe eczema.

Our dermatology FDA recap for the first half of 2024 includes our top 5 approvals, 3 decisions to watch in the second half of 2024, and a podcast episode with James Del Rosso, DO

Cook explains to HCPLive how elite athletes can optimize sleep for peak performance.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.

Diana Girnita, MD, PhD, highlights the crucial role of patient education, the integration of traditional and integrative medicine, and the importance of reliable information for improving health outcomes in chronic conditions.

Our June 2024 month-in-review includes the latest pipeline news, the impact of vision issues on public health, and expert-led insight on the latest in ophthalmology.

These data highlight the results of an international sample of adult patients with allergies to certain food products and caregivers of children with food allergies.

Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

The panel offers their final recommendations for physicians managing patients with asthma.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.

Shai Efrati, MD, explains how his research aims to address the root cause of fibromyalgia: damaged brain tissue.

In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.

This analysis explores the burden level in pediatric and adolescent eczema patients within Japan, highlighting associated burden on caregivers/families and other factors.

Gozal told HCPLive about the issue of the classic approach when diagnosing children with OSA.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

Addressing patients with HIV who have fallen out of care, Shauna Applin, ARNP, provides clinical insights on treatment options and best practices for restarting therapy.

The study demonstrated clinical similarity between the proposed biosimilar and the reference products.

In this episode, Veeral Sheth, MD speaks with Alkeus Pharmaceutical's CMO on the company's lead candidate for Stargardt disease and the TEASE clinical trial program.

These findings were referenced by skincare brand CeraVe, highlighting the need for skin health education as well as skin health barriers.